Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of pembrolizumab + gemcitabine in HER2-negative advanced breast cancer
2016-001779-54Phase 2Completed
- Sponsor
- GEICAM
- Start
- Nov 2016
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and gemcitabine in breast cancer, sponsored by GEICAM. Primary endpoint: Dose Limiting Toxicity incidence (run-in phase). Started Nov 2016; status: completed.
02
Drugs
pembrolizumabgemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-001779-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001779-54.